The global prefilled syringe market is expected to reach US$ 6.698 billion in 2022 to US$ 15.003 billion by 2030; the market is estimated to record a CAGR of 10.6% from 2022 to 2030.
The prefilled syringe market growth is attributed to increasing prevalence of chronic disorders and growing adoption of self-injecting parenteral devices. However, increasing product recalls is hindering the market growth.
Other chronic conditions such as Crohn’s disease, multiple sclerosis, and cardiovascular disorders require frequent drug administration for disease management and treatment. As per the WHO, cardiovascular disorders are the leading cause of death - nearly 17.9 million deaths are reported every year due to cardiovascular disorders. It has become a new standard for injectable drug delivery among large patient populations globally. Moreover, these prefilled syringes can be used by a large patient population with minimal training and do not require constant assistance from healthcare professionals, owing to which prefilled syringes are adopted largely in professional healthcare environments as well as home healthcare settings, thereby driving the prefilled syringes market growth.
The prefilled syringe market, by type, is bifurcated into disposable prefilled syringes and reusable prefilled syringes. In 2022, the disposable prefilled syringes segment held a larger market share and is estimated to register a faster CAGR during 2022-2030. Prefilled disposable syringes are designed to be used once, after which they are discarded to reduce the risk of contamination and infections. These syringes are used in healthcare settings for the administration of medications, vaccines, and other injectables. They can also be used in home healthcare settings for the self-administration of injectables at regular intervals. Prefilled disposable syringes are available in different types such as insulin syringes, allergy syringes, and tuberculin syringes, with varying sizes. Moreover, the increased use of prefilled autoinjectors has generated the demand for disposable prefilled syringes as they are sold as a single dose. Moreover, increasing cases of allergies and infections among large populations, coupled with stringent safety guidelines from health ministries and other regulatory bodies worldwide, is expected to fuel the growth of disposable prefilled syringes.
Based on distribution channel, the prefilled syringe market is segmented into hospital pharmacy, retail pharmacy, and online channel. In 2022, the hospital pharmacy segment held the largest market share and is estimated to register the fastest CAGR during 2022-2030. Hospital pharmacies are an essential part of healthcare systems. Located within hospital premises, these pharmacies operate as key distribution centers of prescription products. They provide medications and other pharmaceutical products to patients receiving treatment or care in corresponding hospitals. These pharmacies are responsible for ensuring that medications are stored, prepared, and dispensed safely and accurately for hospital usage. They are also responsible for providing clinical pharmacy services to support patient care. Further, hospital pharmacies may engage in medication management, drug utilization review, and medication education for patients and healthcare providers. Hospital pharmacies are one of the most common channels of distribution for prefilled syringes as it is easy for the patient to buy prescribed medication in prefilled syringes after every visit.
According to the Diabetes Research Institute, the number of people with diabetes in the US was ~37.3 million (11.3% of the population) in 2022. Nearly 28.7 million people in the US were diagnosed with diabetes, and approximately 8.6 million people have undiagnosed diabetes. Further, ~1.4 million diabetes cases are diagnosed each year in the US. According to the Centers for Disease Control and Prevention, in 2020, ~88 million adults had prediabetes, which is 34.5% of the US adult population. According to Yale researchers, in 2022, ~30 million people in the US have diabetes, and about 7 million require daily insulin.
There is an increase in the demand for infertility treatment in the US. According to the CDC, in 2022, ~22% married couples, with women aged above 30 years, have problems in conceiving their first child. To overcome with infertility issues, various treatments are available in the market through prefilled syringes. In July 2023, Fresenius Kabi launched Ganirelix Acetate Injection, a generic fertility drug, in 250 mcg/0.5 ml prefilled syringes as part of the company’s expansion in women’s health. Therefore, the increasing prevalence of diabetes and other disorders, along with surge in product launches, is expected to drive the growth of prefilled syringes market in the US.
Several market players are adopting organic strategies to stay competitive in the market. For instance, - In April 2023, Delta Med Group partnered with DBM, a leading manufacturer of prefilled syringes. Delta Med Group and DBM will expand their portfolio, profiting from highly complementary products and R&D capabilities, improving their ability to serve customers. The partnership will generate significant synergies and boost the growth trajectory of the combined entity.
The prefilled syringe market growth is attributed to increasing prevalence of chronic disorders and growing adoption of self-injecting parenteral devices. However, increasing product recalls is hindering the market growth.
Increasing Prevalence of Chronic Disorders to Develop Prefilled Syringe
The growing aging population and changes in social behavior and lifestyle contribute to some of the common long-term health conditions. As per the World Health Organization (WHO), the prevalence of chronic lifestyle diseases is expected to increase by 57% by the end of 2026. The emerging markets will be hit hardest, as a population explosion is expected in developing countries. With the increasing urbanization, people are more inclined toward a sedentary lifestyle, which results in rheumatoid arthritis, diabetes, and others. Diabetes is one of the major global health issues of the 21st century. According to the International Diabetes Federation (IDF), the number of people with diabetes in North America was about 46 million in 2019 and is projected to reach 62 million by 2045. The increase in disease prevalence is approximated to be 35% during the projection period.Other chronic conditions such as Crohn’s disease, multiple sclerosis, and cardiovascular disorders require frequent drug administration for disease management and treatment. As per the WHO, cardiovascular disorders are the leading cause of death - nearly 17.9 million deaths are reported every year due to cardiovascular disorders. It has become a new standard for injectable drug delivery among large patient populations globally. Moreover, these prefilled syringes can be used by a large patient population with minimal training and do not require constant assistance from healthcare professionals, owing to which prefilled syringes are adopted largely in professional healthcare environments as well as home healthcare settings, thereby driving the prefilled syringes market growth.
Prefilled Syringe Market:
Segmental Overview
The prefilled syringe market is segmented on the basis of type, material, product type, application, distribution channel, and geography.The prefilled syringe market, by type, is bifurcated into disposable prefilled syringes and reusable prefilled syringes. In 2022, the disposable prefilled syringes segment held a larger market share and is estimated to register a faster CAGR during 2022-2030. Prefilled disposable syringes are designed to be used once, after which they are discarded to reduce the risk of contamination and infections. These syringes are used in healthcare settings for the administration of medications, vaccines, and other injectables. They can also be used in home healthcare settings for the self-administration of injectables at regular intervals. Prefilled disposable syringes are available in different types such as insulin syringes, allergy syringes, and tuberculin syringes, with varying sizes. Moreover, the increased use of prefilled autoinjectors has generated the demand for disposable prefilled syringes as they are sold as a single dose. Moreover, increasing cases of allergies and infections among large populations, coupled with stringent safety guidelines from health ministries and other regulatory bodies worldwide, is expected to fuel the growth of disposable prefilled syringes.
Based on distribution channel, the prefilled syringe market is segmented into hospital pharmacy, retail pharmacy, and online channel. In 2022, the hospital pharmacy segment held the largest market share and is estimated to register the fastest CAGR during 2022-2030. Hospital pharmacies are an essential part of healthcare systems. Located within hospital premises, these pharmacies operate as key distribution centers of prescription products. They provide medications and other pharmaceutical products to patients receiving treatment or care in corresponding hospitals. These pharmacies are responsible for ensuring that medications are stored, prepared, and dispensed safely and accurately for hospital usage. They are also responsible for providing clinical pharmacy services to support patient care. Further, hospital pharmacies may engage in medication management, drug utilization review, and medication education for patients and healthcare providers. Hospital pharmacies are one of the most common channels of distribution for prefilled syringes as it is easy for the patient to buy prescribed medication in prefilled syringes after every visit.
Prefilled Syringe Market:
Geographical Overview
In terms of geography, the global Prefilled Syringe market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is anticipated to hold the largest market share during 2022-2030. The North America prefilled syringes market is segmented into the US, Canada, and Mexico. The growth of the prefilled syringes market in the region is mainly due to the increased adoption of self-injecting parenteral devices and a surge in home healthcare to treat chronic diseases in the region.According to the Diabetes Research Institute, the number of people with diabetes in the US was ~37.3 million (11.3% of the population) in 2022. Nearly 28.7 million people in the US were diagnosed with diabetes, and approximately 8.6 million people have undiagnosed diabetes. Further, ~1.4 million diabetes cases are diagnosed each year in the US. According to the Centers for Disease Control and Prevention, in 2020, ~88 million adults had prediabetes, which is 34.5% of the US adult population. According to Yale researchers, in 2022, ~30 million people in the US have diabetes, and about 7 million require daily insulin.
There is an increase in the demand for infertility treatment in the US. According to the CDC, in 2022, ~22% married couples, with women aged above 30 years, have problems in conceiving their first child. To overcome with infertility issues, various treatments are available in the market through prefilled syringes. In July 2023, Fresenius Kabi launched Ganirelix Acetate Injection, a generic fertility drug, in 250 mcg/0.5 ml prefilled syringes as part of the company’s expansion in women’s health. Therefore, the increasing prevalence of diabetes and other disorders, along with surge in product launches, is expected to drive the growth of prefilled syringes market in the US.
Several market players are adopting organic strategies to stay competitive in the market. For instance, - In April 2023, Delta Med Group partnered with DBM, a leading manufacturer of prefilled syringes. Delta Med Group and DBM will expand their portfolio, profiting from highly complementary products and R&D capabilities, improving their ability to serve customers. The partnership will generate significant synergies and boost the growth trajectory of the combined entity.
- In October 2022, Hikma Pharmaceuticals PLC (Hikma) launched Succinylcholine Chloride Injection, USP, in prefilled syringe (PFS) form in the US. The 100 mg/5 ml PFS is the first FDA-approved PFS to be released in the market.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Prefilled Syringes Market Landscape
5. Prefilled Syringes Market - Key Industry Dynamics
6. Prefilled Syringes Market - Global Market Analysis
7. Prefilled Syringes Market Analysis - Type
8. Prefilled Syringes Market Analysis - Material
9. Prefilled Syringes Market Analysis - Design
10. Prefilled Syringes Market Analysis - Application
11. Prefilled Syringes Market Analysis - Distribution Channel
12. Prefilled Syringes Market - Geographical Analysis
13. Prefilled Syringes Market - Impact of COVID-19 Pandemic
14. Competitive Landscape
15. Industry Landscape
16. Company Profiles
17. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Gerresheimer AG
- Schott Group
- Nipro Medical Corporation
- BD
- Baxter International Inc.
- Terumo
- YPSOMED
- Weigao group
- B Barun
- Deltamed
